Eli Lilly Acquires Atai Beckley for $2.8B to Develop Psychedelic Depression Drug
Eli Lilly (LLY) has acquired psychedelics company Atai Beckley for $2.8 billion. The deal aims to develop a DMT-like nasal spray for depression, with pivotal trial data expected by 2029.
Key Numbers
Eli Lilly (LLY) has acquired psychedelics company Atai Beckley for $2.8 billion, according to 24/7 Wall St. The acquisition targets the development of a DMT-like nasal spray for depression, with pivotal trial data expected by 2029.
Deal Details
| Item | Detail |
|---|---|
| Value | $2.8 billion |
| Payment | Cash (per source) |
| Lead Product | DMT-like nasal spray for depression |
| Pivotal Data Expected | 2029 |
| Acquirer | Eli Lilly (LLY) |
| Target | Atai Beckley |
Rationale
This acquisition reflects Big Pharma's growing interest in novel psychiatric treatments, particularly for treatment-resistant depression. Lilly sees psychedelics as a potential breakthrough, similar to ketamine's success. Investing in a product with distant data underscores confidence in the mechanism.
Regulatory Challenges
Psychedelics face significant regulatory hurdles, as most remain Schedule I substances in the U.S. Development requires FDA approvals and extensive clinical trials, which may take years. Social and medical acceptance is also limited.
Impact on Stocks
No immediate stock reaction for LLY was reported. The deal signals a long-term strategy that could affect valuation if trials succeed. Johnson & Johnson (JNJ) may benefit from sector momentum but is not directly involved.
Frequently Asked Questions
Found this useful? Share it